Kiora Stock Story


USD 0.41  0.01  2.50%   

Given the investment horizon of 60 days Kiora Pharmaceuticals is expected to under-perform the market. In addition to that, the company is 4.83 times more volatile than its market benchmark. It trades about -0.09 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.08 per unit of volatility. While many risk-averse investors are getting carried away by overanalyzing healthcare space, it is reasonable to break down Kiora Pharmaceuticals. We are going to inspect if the current expected returns justify Kiora Pharmaceuticals' volatility.
Published over a month ago
View all stories for Kiora Pharmaceuticals | View All Stories
Is Kiora Pharmaceuticals way too volitale for you?
The company currently holds 209.41 K in liabilities with Debt to Equity (D/E) ratio of 0.02, which may suggest Kiora Pharmaceuticals is not taking enough advantage from borrowing. Kiora Pharmaceuticals has a current ratio of 5.48, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Kiora Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Kiora Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Kiora Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Kiora to invest in growth at high rates of return. When we think about Kiora Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
The company secures a Beta (Market Risk) of 1.2379, which conveys a somewhat significant risk relative to the market. Let's try to break down what Kiora's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Kiora Pharmaceuticals will likely underperform. Even though it is essential to pay attention to Kiora Pharmaceuticals price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Kiora Pharmaceuticals exposes twenty-one different technical indicators, which can help you to evaluate its performance. Kiora Pharmaceuticals has an expected return of -0.61%. Please be advised to verify Kiora Pharmaceuticals standard deviation, value at risk, as well as the relationship between the Value At Risk and kurtosis to decide if Kiora Pharmaceuticals performance from the past will be repeated at some point in the near future.
Volatility is a rate at which the price of Kiora Pharmaceuticals or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Kiora Pharmaceuticals may increase or decrease. In other words, similar to Kiora's beta indicator, it measures the risk of Kiora Pharmaceuticals and helps estimate the fluctuations that may happen in a short period of time. So if prices of Kiora Pharmaceuticals fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility.
Please read more on our technical analysis page.

Watch out for price decline

Please consider monitoring Kiora Pharmaceuticals on a daily basis if you are holding a position in it. Kiora Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Kiora Pharmaceuticals stock to be traded above the $1 level to remain listed. If Kiora Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How important is Kiora Pharmaceuticals's Liquidity

Kiora Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Kiora Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Kiora Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Kiora Pharmaceuticals's total debt and its cash.

How does Kiora utilize its cash?

To perform a cash flow analysis of Kiora Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Kiora Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Kiora Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Kiora Pharmaceuticals Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Kiora Pharmaceuticals reported Net Cash Flow from Operations of (10.89 Million) in 2021

Kiora Pharmaceuticals Volatility Drivers

Kiora Pharmaceuticals unsystematic risk is unique to Kiora Pharmaceuticals and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Kiora Pharmaceuticals you can also buy General Electric. You can also mitigate this risk by investing in the biotechnology sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Kiora Pharmaceuticals important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Kiora Pharmaceuticals income statement and balance sheet. Here are more details about Kiora volatility.